Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(80)
•••
Post by bealerton Jan 24, 2024 10:52am
156 Views
Post# 35842900

Terrific Press Release

Terrific Press ReleaseTo a newcomer, this press release sounds like we have a BILLION DOLLAR COMPANY on the go here.

I personally can't wait for the excitement to see the stock rise up from the ashes of 11 or 12 cents and it  appears that there has been no trading yet today after this enticing press release.  Is this for real???

Come on you astute investors;  can't you see the potential here?  Get your bids in early to avoid the panic rush or experience yet another FOMO.

THE FUTURE LOOKS SOOOOO BRIGHT AFTER ALL THESE YEARS OF WAITING.

One thing I will hand to the person who created the press release is that it has been professionally written and very enticing to garner new shareholders immediately.

GLTA

BeAlert
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities